byannli (previously paliperidone janssen-cilag international)
janssen-cilag international n.v. - paliperidonpalmitat - schizofreni - psykoleptiske - byannli (previously paliperidone janssen-cilag international) a 6 monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1 monthly or 3 monthly paliperidone palmitate injectable products (see section 5.
palmeux 75 mg
amdipharm ltd - paliperidonpalmitat - depotinjeksjonsvæske, suspensjon - 75 mg
palmeux 50 mg
amdipharm ltd - paliperidonpalmitat - depotinjeksjonsvæske, suspensjon - 50 mg
palmeux 100 mg
amdipharm ltd - paliperidonpalmitat - depotinjeksjonsvæske, suspensjon - 100 mg
palmeux 150 mg
amdipharm ltd - paliperidonpalmitat - depotinjeksjonsvæske, suspensjon - 150 mg
lacosamide adroiq
extrovis eu ltd. - lakosamid - epilepsi - antiepileptics, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.
spiolto respimat 2.5 mikrog / 2.5 mikrog
boehringer ingelheim international gmbh - tiotropiumbromidmonohydrat / olodaterolhydroklorid - inhalasjonsvæske, oppløsning - 2.5 mikrog / 2.5 mikrog
actilyse 10 mg
boehringer lngelheim international gmbh - alteplase - pulver og væske til injeksjons-/infusjonsvæske, oppløsning - 10 mg
actilyse 20 mg
boehringer lngelheim international gmbh - alteplase - pulver og væske til injeksjons-/infusjonsvæske, oppløsning - 20 mg
actilyse 50 mg
boehringer lngelheim international gmbh - alteplase - pulver og væske til injeksjons-/infusjonsvæske, oppløsning - 50 mg